{"id":"nedaplatin-pemetrexed","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Myelosuppression"},{"rate":"30-50%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Nedaplatin's mechanism involves the formation of platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death. Pemetrexed, on the other hand, inhibits key enzymes involved in folate metabolism, resulting in the depletion of essential nucleotides required for DNA synthesis and cell proliferation.","oneSentence":"Nedaplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while pemetrexed is an antifolate drug that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to DNA synthesis inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:49.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT01951482","phase":"PHASE3","title":"Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Non Squamous Non-small Cell Lung Cancer, Brain Metastases, Bevacizumab","enrollment":160},{"nctId":"NCT06775275","phase":"PHASE2","title":"A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2024-09-24","conditions":"Resectable Lung Non-Small Cell Carcinoma","enrollment":60},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT06231680","phase":"PHASE2","title":"Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2024-01-19","conditions":"Lung Cancer, Nonsmall Cell, Esophageal Carcinoma","enrollment":132},{"nctId":"NCT05648071","phase":"PHASE3","title":"First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2021-12-01","conditions":"Advanced Non-squamous Non-Small-Cell Lung Cancer","enrollment":60},{"nctId":"NCT01951469","phase":"PHASE3","title":"Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Non-small Cell Lung Cancer, Brain Metastases, EGFR Mutation","enrollment":160},{"nctId":"NCT02607592","phase":"PHASE3","title":"A Prospective Multi-center Phase III Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Carcinoma，Non-Small-Cell Lung","enrollment":293},{"nctId":"NCT02777788","phase":"PHASE2, PHASE3","title":"Curative Study of Chinese Traditional Medicine to Treat Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2014-09","conditions":"Cancer","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"nedaplatin+pemetrexed","genericName":"nedaplatin+pemetrexed","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nedaplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while pemetrexed is an antifolate drug that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to DNA synthesis inhibition. Used for Non-small cell lung cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}